Virax Biolabs Group Limited (VRAX)

NASDAQ: VRAX · USD

$1.06

-0.04 (-3.6%)· Recorded snapshot

Market cap	844.8K
Revenue (ttm)	12.4K
Net income (ttm)	-5M
EPS (ttm)	-$12.6
Shares out	797K
Volume	33,715.877
Beta	1.39

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 12.4K
Net income (ttm): -5M
EPS (ttm): -$12.6
Market cap: 844.8K

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Conserver

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-78.6

P25 n/aP50 n/aP75 n/a

ROIC-58.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VRAX indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001885827
Company name	Virax Biolabs Group Limited
Country	United Kingdom
Country code	US
CUSIP number	G9495L133
Earnings date	2026-11-20
Employees	26
Employees change	7
Employees growth	36.84%
Enterprise value	$-5.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-03-31
First seen	2026-05-09
Fiscal year end	March
Founded	2013
Industry	Biotechnology
IPO date	2022-07-21
Is primary listing	Yes
Is SPAC	No
ISIN number	KYG9495L1335
Last 10-K release date	2026-07-06
Last earnings date	2026-09-01
Last refreshed	2026-11-04
Last stock split date	2026-06-26
Last stock split type	Reverse
Market cap	$844,807
Market cap category	Nano-Cap
Next earnings date	2026-11-20
Options	No
Price	$1.06
Price currency	USD
Sector	Healthcare
SIC code	2835
Stock price date	2026-11-03
Symbol	VRAX
Website	https://viraxbiolabs.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-1,192.45%
FCF / EV yield	92.75%
FCF yield	-577.38%
P/B ratio	0.08x
P/S ratio	68x
Price / tangible book value	0.11x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	61.9%
Operating margin	-51,515.17%
Pretax margin	-47,753.55%
Profit per employee	$-193,221
Revenue per employee	$478
ROA	-54.23%
ROA (5Y)	-538.87%
ROCE	-83.77%
ROE	-78.65%
ROIC	-58.87%
SBC / revenue	1,049.74%
Tax / revenue	-7,246.56%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Gross profit growth (Q)	-84.02%
Net income growth years	2
Revenue growth	96.23%
Revenue growth (Q)	684.83%
Revenue growth (QoQ)	572.57%
Revenue growth 3Y	13.21%
Revenue growth 5Y	-36.86%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-255,831
Depreciation and amortization	$351,581
EBIT	$-6.4M
EBITDA	$-6M
EPS	$-12.64
FCF per share	$-6.12
Financing cash flow	$7.1M
Free cash flow	$-4.9M
Free cash flow minus SBC	$-5M
Gross profit	$7,690
Income taxes	$-900,240
Investing cash flow	$-255,831
Net borrowing	$4.3M
Net cash flow	$2.2M
Net income	$-5M
Operating cash flow minus SBC	$-4.8M
Operating income	$-6.4M
Revenue	$12,423
Stock-based compensation	$130,409

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-4.82
Book value per share	$13.08
Debt / equity	0.06
Interest coverage	-103.6
Long-term assets	$1.5M
Long-term liabilities	$304,808
Net cash (debt)	$6.1M
Net cash / market cap	722.51%
Net cash growth	77.32%
Net debt / equity	-0.83
Piotroski F-Score	4
Property, plant and equipment	$1.5M
Shareholders' equity	$7.3M
Tangible book value	$7.6M
Tangible book value per share	$13.08
Total assets	$8.3M
Total cash	$6.5M
Total debt	$414,387
Total liabilities	$989,832
WACC	11.84%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0
Current assets	$6.8M
Current liabilities	$685,024
Current ratio	9.97
Inventory turnover	0.04
Net working capital	$-265,052
Quick ratio	9.55
Working capital	$6.1M
Working capital turnover	0

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-166.46%
Dividend yield	0%
Shareholder yield	-166.46%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.29
1D price change	-3.64%
1M price change	-51.82%
1M total return	-51.82%
1W price change	-10.92%
1W total return	-10.92%
1Y price change	-92.46%
1Y return CAGR	-92.47%
1Y total return	-92.46%
20-day SMA	$1.46
200-day SMA	$3.84
3M price change	-59.54%
3M total return	-59.54%
3Y price change	-98.37%
3Y return CAGR	-74.63%
3Y total return	-98.37%
50-day SMA	$2.10
50-day SMA vs 200-day SMA	50under200
52-week high	$21.75
52-week high date	2025-12-03
52-week low	$1.04
52-week low date	2026-11-03
6M price change	-67.83%
6M total return	-67.83%
After-hours change	0.94%
After-hours close	$1.06
After-hours price	$1.07
All-time high	$7,250.00
All-time high date	2022-07-29
All-time low	$1.04
All-time low date	2026-11-03
Average true range (ATR)	$0.18
Average volume	47.1K
Beta (1Y)	3.58
Beta (2Y)	2.1
Beta (5Y)	1.39
Change from 52-week high	-95.13%
Change from 52-week low	1.92%
Change from all-time high	-99.99%
Change from all-time low	1.92%
Change from open	-2.75%
Day's gap	-0.91%
Dollar volume	$35,739
High price	$1.18
Low price	$1.04
Monthly RSI	14.49
Open price	$1.09
Position in 52-week range	14.81%
Premarket change	6.6%
Premarket close	$1.06
Premarket price	$1.13
Premarket volume	2.8K
Previous close	$1.10
Price vs 150-day SMA	-67.73%
Price vs 20-day SMA	-27.2%
Price vs 200-day SMA	-72.42%
Price vs 50-day SMA	-49.6%
Relative volume	0.72
Return from IPO open	-99.98%
Return from IPO price	-78.8%
RSI	23.59
Sharpe ratio	-0.59
Sharpe ratio (3Y)	-0.05
Sortino ratio	-1.2
Sortino ratio (3Y)	-0.05
Volume	33.7K
Weekly RSI	31.84
YTD price change	-87.74%
YTD total return	-87.74%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	720.7K
Float percentage	90.43%
Shares change (QoQ)	217.37%
Shares change (YoY)	166.46%
Shares held by insiders	4.55%
Shares held by institutions	3.31%
Shares outstanding	797K
Short % of float	1.25%
Short % of shares	1.13%
Short ratio	0.1 days

Deeper analysis on VRAX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this VRAX report

Is a complete VRAX research report available?

No complete published report is available for Virax Biolabs Group Limited (VRAX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Virax Biolabs Group Limited (VRAX)

Price

Financial snapshot

Fair-value bridge

Latest news · VRAX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All VRAX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VRAX

Frequently asked questions